IHAM
Integral Health Asset Management Portfolio holdings
AUM
$1.07B
This Quarter Return
-6.53%
1 Year Return
+40.53%
3 Year Return
+328.04%
5 Year Return
+535.34%
10 Year Return
–
AUM
$384M
AUM Growth
+$384M
(+7.1%)
Cap. Flow
+$55.4M
Cap. Flow
% of AUM
14.41%
Top 10 Holdings %
Top 10 Hldgs %
35.81%
Holding
89
New
18
Increased
39
Reduced
11
Closed
17
Top Buys
| 1 |
Elevance Health
ELV
|
$9.82M |
| 2 |
CRISPR Therapeutics
CRSP
|
$7.53M |
| 3 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$7.2M |
| 4 |
Guardant Health
GH
|
$6.62M |
| 5 |
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
|
$6.22M |
Top Sells
| 1 |
McKesson
MCK
|
$13.7M |
| 2 |
Abbott
ABT
|
$9.85M |
| 3 |
Fate Therapeutics
FATE
|
$7.61M |
| 4 |
AbbVie
ABBV
|
$6.77M |
| 5 |
Centene
CNC
|
$6.31M |
Sector Composition
| 1 | Healthcare | 97.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Cigna
CI
$80.2B
| $5.99M | 1.56% |
+25,000
| New | +$5.99M |
|
27
Heron Therapeutics
HRTX
$204M
| $5.72M | 1.49% |
1,000,000
+250,000
| +33% | +$1.43M |
|
|
ONEM
28
DELISTED
1Life Healthcare, Inc. Common Stock
ONEM
| $5.54M | 1.44% |
500,000
+225,000
| +82% | +$2.49M |
|
29
Jazz Pharmaceuticals
JAZZ
$7.99B
| $5.45M | 1.42% |
+35,000
| New | +$5.45M |
|
30
Kura Oncology
KURA
$732M
| $5.42M | 1.41% |
337,000
+252,000
| +296% | +$4.05M |
|
31
SI-BONE Inc
SIBN
$700M
| $5.31M | 1.38% |
235,000
+60,000
| +34% | +$1.36M |
|
32
Intuitive Surgical
ISRG
$158B
| $4.83M | 1.26% |
+16,000
| New | +$4.83M |
|
33
Agilon Health
AGL
$497M
| $4.44M | 1.15% |
175,000
+50,000
| +40% | +$1.27M |
|
34
Keros Therapeutics
KROS
$640M
| $4.41M | 1.15% |
81,000
+46,000
| +131% | +$2.5M |
|
35
Aclaris Therapeutics
ACRS
$223M
| $4.1M | 1.07% |
238,000
+38,000
| +19% | +$655K |
|
36
Zimmer Biomet
ZBH
$20.8B
| $3.84M | 1% |
+30,000
| New | +$3.84M |
|
37
Intellia Therapeutics
NTLA
$1.26B
| $3.63M | 0.95% |
50,000
| – | – |
|
|
NVRO
38
DELISTED
NEVRO CORP.
NVRO
| $3.62M | 0.94% |
50,000
+15,000
| +43% | +$1.09M |
|
39
Insmed
INSM
$30.3B
| $3.53M | 0.92% |
150,000
+70,000
| +88% | +$1.65M |
|
40
Arcturus Therapeutics
ARCT
$467M
| $3.37M | 0.88% |
125,000
+60,000
| +92% | +$1.62M |
|
41
Zai Lab
ZLAB
$3.48B
| $3.3M | 0.86% |
+75,000
| New | +$3.3M |
|
42
Neurocrine Biosciences
NBIX
$13.5B
| $3.28M | 0.85% |
+35,000
| New | +$3.28M |
|
43
Biogen
BIIB
$20.8B
| $3.16M | 0.82% |
15,000
-20,000
| -57% | -$4.21M |
|
44
Mirum Pharmaceuticals
MIRM
$3.75B
| $3.08M | 0.8% |
140,000
+40,000
| +40% | +$881K |
|
45
uniQure
QURE
$954M
| $3.07M | 0.8% |
170,000
+70,000
| +70% | +$1.26M |
|
46
Regenxbio
RGNX
$498M
| $2.99M | 0.78% |
90,000
+15,000
| +20% | +$498K |
|
47
Teleflex
TFX
$5.57B
| $2.84M | 0.74% |
+8,000
| New | +$2.84M |
|
48
Akero Therapeutics
AKRO
$3.65B
| $2.84M | 0.74% |
200,000
+115,000
| +135% | +$1.63M |
|
49
Replimune Group
REPL
$460M
| $2.8M | 0.73% |
165,000
+65,000
| +65% | +$1.1M |
|
50
Atara Biotherapeutics
ATRA
$88.7M
| $2.79M | 0.73% |
12,000
+4,000
| +50% | +$929K |
|